<DOC>
	<DOCNO>NCT02217137</DOCNO>
	<brief_summary>Rheumatoid Arthritis ( RA ) Systemic Lupus Erythematosus ( SLE ) chronic systemic autoimmune disease report affect ocular surface patient [ 1,2 ] . However , nature disturbance ocular surface immunity relationship systemic disease severity poorly understood . This study aim profile ocular surface inflammation RA SLE patient a. , analyse level tear cytokine , b. , investigate conjunctival cell , c. clinical imaging conjunctival redness tear stability . 20 consecutive RA patient 20 consecutive SLE patient recruit Singapore General Hospital Rheumatology clinic . 20 age match control SLE another 20 age match control RA recruit . All participant undergo 1 . Tear collection Schirmer strip 2 . EyePRIMTM ( Opia Technologies ) Impression Cytology Device conjunctival sample 3 . Clinical ocular surface assessment Oculus Keratograph 5M 4 . Collection blood via venipuncture ( optional ) 5 . Retrieval Clinical Information participants The association cytokines tear various cellular immune marker , well clinical sign inflammation tear stability investigate . This useful longitudinal study treatment autoimmmune disease patient .</brief_summary>
	<brief_title>Tear Proteins , Conjunctival Cells Imaging Eyes Rheumatoid Arthritis Systemic Lupus Erythematosus Patients</brief_title>
	<detailed_description>Background Rationale Inflammatory autoimmune disease eye involvement Rheumatoid Arthritis ( RA ) Systemic Lupus Erythematosus ( SLE ) chronic systemic autoimmune disease unknown etiology [ 2 ] . Ocular manifestation may range condition cause distress symptom discomfort , dry eye syndrome , potentially sight-threatening condition retinal vasculitis . The ocular surface agree site commonly affect systemic autoimmune disease , manifest dry eye syndrome . However , related complication poorly address [ 1,2 ] . The severity ocular surface inflammation may relate systemic immunology since systemic treatment alter sign ocular surface disease . EyePRIMTM ( Opia Technologies ) Impression Cytology Device Studies show method combine flow cytometry OSIC useful phenotype recover cell superficial layer ocular surface [ 3 ] . There recent advance clinical technique obtain conjunctival cell reseach study . An example award win device EyePRIMTM ( Opia Technologies ) . Previous study show EyePRIMTM able obtain sufficient cell flow cytometry immune marker [ 4 ] . In study , ocular surface three healthy patient analyse use EyePRIMTM conventional semi-circular Supor PES filter flow cytometry . One EyePRIMTM use impression lateral bulbar conjunctiva second , medial bulbar conjunctiva eye . Cells recover EyePRIMTM use gentle agitation pipette tip one minute , stain antibody marker leukocytes ( CD45 ) , CD16 , epCAM , HLA-DR dead cell exclusion dye . Results show mean correct total cell count collect use EyePRIMTM great conventional method ( 475,544 cell vs 335,226 cell ) . Out total cell collect , mean correct number lymphocytes found via stain CD45 antibody around 1000 . Advances clinical phenotyping Dry eye common ocular surface disease mediate inflammation . It postulate dry eye context systemic autoimmune disease cause infiltration activate T lymphocytes bulbar conjunctiva , begin vicious cycle chronic inflammation ocular surface [ 5 ] . In dry eye database SNEC/SERI ( unpublished data ) , find high level fluorescein corneal staining , indicate presence punctate epithelial erosion patient RA compare dry eye patient without systemic autoimmune disease . While personally conduct study SLE patient , document exist literature significant sign dry eye detect SLE patient use old assessment modality Schirmer 's test Rose Bengal stain [ 6 ] . Lastly , availability new phenotyping equipment Oculus Keratograph 5M provide opportunity clinical parameter conjunctival redness non-invasive tear break time ( NIBUT ) assess objectively , accurately non-invasively [ 7 ] . To best investigator ' knowledge , standardise tool use context rheumatological disease effect ocular surface . Research experience SERI In SERI significant experience clinical imaging study ocular surface . The clinical profile ocular surface inflammation objectively measure document use newly available image technique describe . In addition , TCR grant jointly apply coming month examine systemic well ocular immune event treatment rheumatology patient include RA SLE . Preliminary data Our research team experience extraction tear protein schirmer strip longitudinal trial analyse patient 's visit , tear cytokine concentration IL-1b , IL-2 , IL-4 , IL-6 , IL-8 , IL-10 , IFN , TNFa , IL-12 , IL-13 , IL-17a , MCP , MIP1a , MMP9 , IP10 , RANTES use BioPlex technique ( Figure 1 ) . In study ( unpublished data ) , research group successfully perform flow cytometry , evaluate proportion various immune cell type stain cell surface marker . This study perform pterygium tissue . We able perform intracytoplasmic stain cytokine Phorbol Myristate Acetate ( PMA ) stimulation . This performed Th1 ( eg . TNFα IFN γ ) Th17 ( eg . IL-17a ) cytokine , population T lymphocytes 300-500 . 1 . HYPOTHESIS AND OBJECTIVES Hypothesis specific aim This study thus aim profile ocular surface inflammation RA SLE patient a. , analyse level tear cytokine , b. , investigate conjunctival cell , c. clinical imaging conjunctival redness tear stability . In conjunctiva patient , expect find conjunctival epithelial cell , stromal fibroblast well various immune cell . Study Objectives Purpose 1 . A primary purpose study profile A. tear cytokine level B. proportion various immune cell ( eg. , lymphocyte , dendritic cell neutrophil subset ) conjunctival impression . 2 . The secondary aim profile immune response , either examine possible Th1 Th17 responses T cell stimulation , level inflammatory gene transcript , ie. , pattern immune gene expression . 3 . A third aim study correlation activity systemic disease , ocular surface status , tear cytokine immune cell level RA SLE patient . Outcomes 1 . Tear cytokine level 2 . Conjunctival immune cell profile 1 . Proportion T lymphocytes immune cell 2 . Immune gene expression 3 . Clinical parameter ocular surface : Conjunctival redness , tear meniscus height NIBUT 4 . Rheumatological disease activity indices patient Primary outcome : Tear cytokine level conjunctival immune cell profile RA SLE patient comparison healthy control 2 . EXPECTED RIKS AND BENEFITS Expected risk No potential problem expect study . Potential benefit With great understand presence various inflammatory mediator , gain insight complex process take place . It also possible marker like tear protein biomarkers warn individual systemic flare . We jointly file provisional patent tear biomarkers SLE flare . ( Date Filing : 11 September 2013 Singapore Provisional Patent Application No . : 201306892-9 ) . 3 . STUDY POPULATION 3.1 . List number nature subject enrol . Participants target sample size 20 consecutive RA patient 20 consecutive SLE patient , age 21 99 , recruit Singapore General Hospital , three setting a. , SGH Rheumatology outpatient b. , Rheumatology patient ward , c. , Patients pilot project Dr Tan ( CIRB REF : 2013/152/E ) . Permission would seek attend doctor subject recruit . Eligible subject counsel study study coordinator . If subject interested , study coordinator accompany subject SERI relevant assessment . Informed write consent obtain participant . In addition , recruit 20 age match control SLE similarly another 20 control RA . If old control require , pre-cataract patient , young one volunteer student . They undergo assessment patient group . Publicity study carry via poster word mouth ( draft poster submit approval ) . 3.2 . Inclusion Criteria 1 . Clinically diagnosed Rheumatoid Arthritis Systemic Lupus Erythematosus . 3.3 . Exclusion Criteria All subject meet exclusion criterion baseline exclude participation . 1 . Known history thyroid disorder ( diagnosed physician ) . 2 . No ocular surgery within last 3 month LASIK within 1 year . 3 . Ocular surface disease pterygium , obvious lid/orbital disease lagophthalmos . 4 . Any specified reason determine clinical investigator . 4 . STUDY DESIGN AND PROCEDURES/METHODOLOGY Study Design : Prospective study No . visit : There 1 study visit study . Duration Study : 11 month ( Apr 2014 Mar 2015 ) . Recruitment patient collection data take place 22nd May 2014 31 July 2014 . Procedures : The different procedure propose small study summarize , elaborate upon subsequent paragraph : 1 . Tear collection Schirmer strip 2 . EyePRIMTM ( Opia Technologies ) Impression Cytology Device conjunctival sample 3 . Clinical ocular surface assessment Oculus Keratograph 5M 4 . Collection blood via venipuncture ( optional ) 5 . Retrieval Clinical Information participants 1. a. Schirmer 's I test This do standard strip currently use SERI ( 5 mm wide notch fold ) ( Schirmer Tear Test Strips , Clement Clarke International , UK ) . No prior anaesthetic use . The strip position temporal half lower lid margin eye time . The study participant ask close eye . Any excessive irritation sign note . The extent wet strip record 5 minute test . The strip collect store 1.5ml Eppendorf tube -80˚C cytokine analysis . 1b . Tear cytokine level measurement BioPlex Human Cytokine Assay We propose analyze tear cytokine level tear collect Schirmer strip . In previous study dry eye patient treat punctal occlusion , able elute protein Schirmer strip determine level 15 cytokine . Tear protein extract previous protocol SERI [ 8 ] . Briefly , cut wetted portion strip vortex add phosphate buffer saline protease inhibitor . The assay use commercially available bead base indirect sandwich immunofluorescence assay ( Beadlyte Kit ) . The readout perform Bioplex ( BIO-RAD ) platform . Cytokine standard provide kit use plot standard curve . The level cytokines tear normalise per mm Schirmer analyse . We believe method tear-sample collection effective assessing patient RA/SLE . 2 . Impression cytology Impression cytology perform collect superficial conjunctiva cell analysis . Conjunctiva impression specimen upper bulbar conjunctiva collect EyePRIMTM device . One drop topical anaesthesia ( eg . alcaine ) instill . The eyelid held open thumb forefinger . The distal end device position conjunctiva participant . The inner radius position adjacent limbus . The push-button press membrane contact temporal bulbar conjunctiva , hold 2 3 second . It remove conjunctiva peel motion 2-3 second . The membrane subsequently place RPMI 1640 medium supplement 10 % heat-inactivated fetal calf serum.. This carry temporal bulbar conjunctiva eye . Each participant give single-use container Refresh Plus ® artificial tear self-application case ocular irritation felt impression cytology . The cell process patient 's visit . Cells recover EyePRIMTM filter use gentle agitation pipette tip one minute , stain antibody marker dendritic cell ( lymphoid myeloid ) , NK cell , B cell , T cell , neutrophil monocyte . Specifically , CD123 , CD16 , CD45 , CD56 , CD3 , CD4 , CD8 , CD66b , CD11b , CD11c marker use . Cells harvest impression cytology count undergo flow cytometry depend number , determination proportion immune cell various type , even stain Intracytoplasmic cytokine lymphocytes Phorbol Myristate Acetate stimulation . One modification flow cytometry Amnis microscopy couple flow cytometry perform SingHealth Immunology Inflammation center . Amnis microscopy couple flow cytometry handle even less cell conventional flow cytometry . If cell impression cytology sufficient purpose , nano-string transcript level various immune marker perform instead . 3 . Oculus K 5M image a. Non-Invasive Tear Break-Up Time ( Oculus K5M ) Non-Invasive Tear Break-Up Time measure non-invasively fully automatically use Oculus K5M . The new infrared illumination visible human eye . This prevent glare examination . Patient sit comfortably front instrument blink freely fix target directly ahead . Once participant ready , instructed blink twice refrain blink . Keratograph 5M fully automate capture break distortion image time break note . Three reading take eye get average value . b . Tear Meniscus Height ( Oculus K5M ) This measure non-invasively Oculus K5M near mm . Patient sit comfortably front instrument fix target directly ahead . Tear meniscus capture machine tear meniscus height measure . c. Conjunctival redness ( Oculus K5M ) Conjunctival redness assess use Oculus K5M . Patient sit comfortably front instrument fix target directly ahead . Imaged captured overview display conjunctival redness evaluate `` JENVIS Grading Scale '' . 4 . Collection blood via venipuncture ( optional ) 5-10ml blood collect patient via venipuncture . This optional base participant preference . Two different Participant Information Sheets prepare base choice venipuncture disclose result . This take non-study visit concurrent clinically indicate blood test . 5 . Retrieval Clinical Information participant Three area clinical information rheumatic status participant collect retrospectively . These area : 1 . Most recent serology result autoantibody titre blood test result erythrocyte sedimentation rate 2 . History drug prescription 3 . Disease activity index relevant clinical information We propose obtain data 1 ) 2 ) patient 's electronic medical record via Citrix XenApp portal . Disease activity index clinical information may obtain case file patient . Rationale Small volume fluid use multiplex way determine one cytokine Beadlyte assay , compare ELISA . The EyePRIMTM technique use prior study show high cellular yield success immune profile 3 healthy people . Expected finding : 1 . RA SLE patient elevate tear cytokine level increase inflammatory cell population conjunctival sample . 2 . RA SLE patient great sign ocular surface inflammation healthy control 3 . The sign ocular surface inflammation correlate disease activity , tear cytokine profile conjunctival inflammatory cell profile .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Clinically diagnose Rheumatoid Arthritis Systemic Lupus Erythematosus Known history thyroid disorder ( diagnosed physician ) . No ocular surgery within last 3 month LASIK within 1 year . Ocular surface disease pterygium , obvious lid/orbital disease lagophthalmos . Any specified reason determine clinical investigator .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Tear cytokine immune response</keyword>
</DOC>